Core Viewpoint - Inotiv, Inc. reported a slight revenue increase in Q1 FY 2026, driven by growth in its Discovery and Safety Assessment (DSA) segment, while facing challenges in its Research Models and Services (RMS) segment [1][3][6]. Financial Performance - Total revenue for Q1 FY 2026 was $120.9 million, a 0.8% increase from $119.9 million in Q1 FY 2025, attributed to a $5.1 million (12.0%) rise in DSA revenue, offset by a $4.1 million (5.4%) decline in RMS revenue [2][7][8]. - The consolidated net loss for Q1 FY 2026 was $28.4 million, or 23.5% of total revenue, compared to a net loss of $27.6 million, or 23.0% of total revenue, in Q1 FY 2025 [7][30]. - Adjusted EBITDA for Q1 FY 2026 was $1.8 million, representing 1.5% of total revenue, down from $2.6 million, or 2.2% of total revenue, in Q1 FY 2025 [7][30]. Segment Performance - DSA segment revenue increased to $48.0 million in Q1 FY 2026 from $42.8 million in Q1 FY 2025, reflecting a 12.0% growth [2][8]. - RMS segment revenue decreased to $72.9 million in Q1 FY 2026 from $77.1 million in Q1 FY 2025, marking a 5.4% decline [2][8]. - The DSA backlog was $145.4 million at December 31, 2025, up from $138.2 million at September 30, 2025, and $130.4 million at December 31, 2024 [7]. Operational Insights - The company exited two leased facilities as part of its U.S. site optimization plan during Q1 FY 2026 [5]. - Management emphasized a focus on client service and margin discipline, with a 27% year-over-year growth in DSA net awards, indicating strong demand trends [3][6]. Cash Flow and Capital Structure - Cash and cash equivalents decreased to $12.7 million at December 31, 2025, from $21.7 million at September 30, 2025 [10]. - Cash used in operating activities was $5.4 million for Q1 FY 2026, compared to $4.5 million in Q1 FY 2025 [10][25]. - Total debt as of December 31, 2025, was $405.8 million, up from $402.1 million on September 30, 2025 [10].

Core Viewpoint - Inotiv, Inc. will release its financial results for the fiscal 2026 first quarter on February 9, 2026, before the market opens, and will host a conference call to discuss these results [1]. Company Overview - Inotiv, Inc. is a leading contract research organization that specializes in nonclinical and analytical drug discovery and development services, as well as research models and related products [3]. - The company's focus is on enhancing the efficiency and data quality of drug and medical device development while reducing costs associated with bringing new products to market [3]. - Inotiv is dedicated to supporting research and development objectives, aiming to help researchers maximize the potential of their projects for a healthier and safer world [3].

Group 1 - Curreen Capital reported a return of 10.5% in Q4 2025 and 30.97% for the full year, focusing on "ugly ducklings" that are well-managed and attractively priced [1] - The firm's top five holdings contributed significantly to its performance, with Fortrea Holdings Inc. being a key position [1] - Fortrea Holdings Inc. (NASDAQ:FTRE) is a contract research organization with a market capitalization of $1.553 billion, closing at $16.81 per share on January 30, 2026 [2] Group 2 - Fortrea Holdings Inc. had a one-month return of 1.14% and a 52-week gain of 7.28% [2] - Curreen Capital's investment strategy includes identifying "Crazy Cheap" stocks, where Fortrea is classified due to its significant price drop relative to its downside valuation [3] - Fortrea Holdings Inc. was held by 37 hedge fund portfolios at the end of Q3, a slight decrease from 38 in the previous quarter [4]

Group 1 - Fortrea will release its fourth quarter and full year 2025 financial results on February 26, 2026, before the market opens [1] - A conference call will be held at 8:00 am ET on the same day to review the financial results and conduct a Q&A session [1] - Participants can register for the earnings call on the Fortrea Investor Relations website and should join at least 10 minutes early to avoid delays [2] Group 2 - Fortrea is a leading global provider of clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [3] - The company offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over 30 years of experience across more than 20 therapeutic areas [3] - Fortrea operates in about 100 countries, providing focused and agile solutions to its customers globally [3]

Group 1 - Worldwide Clinical Trials has entered a definitive agreement to acquire Catalyst Clinical Research, an oncology contract research organization (CRO) [1] - The acquisition aims to establish Worldwide as an oncology-focused CRO while expanding its global reach for clinical trials and maintaining depth in several therapeutic areas [2][3] - Catalyst's Board chairman Nick Dyer will join Worldwide's board, and Catalyst's president and CEO Nik Morton will become part of Worldwide's executive leadership team [1][4] Group 2 - The integration will combine Catalyst's solutions, including Catalyst Flex and Catalyst Oncology, with Worldwide's existing portfolio, enhancing service offerings for full-service and functional service provider (FSP) resourcing [2] - The deal includes the adoption of complementary technology platforms and operational practices to improve data efficiency and visibility across the development lifecycle [3] - The transaction is expected to conclude in Q1 2026, pending customary closing conditions and regulatory approvals [3] Group 3 - Worldwide is backed by Kohlberg, while Catalyst is a portfolio company of QHP Capital [4] - Worldwide CEO Alistair Macdonald emphasized that the merger will elevate capabilities in oncology and provide new solutions for customers [4][5] - The combined entity will offer a scalable FSP model with integrated onshore/offshore service lines, leveraging advanced business management tools and AI for operational excellence [5][6]

Core Viewpoint - Charles River Laboratories International, Inc. is set to release its fourth-quarter and full-year 2025 financial results along with guidance for 2026 on February 18, before the market opens [1] Group 1 - A conference call to discuss the financial results and guidance will take place on February 18 at 8:30 a.m. ET [1] - Investors can access a live webcast of the conference call through the Investor Relations section of the company's website [2] - A replay of the conference call will also be available on the same website [2] Group 2 - Charles River Laboratories provides essential products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions globally [3] - The company focuses on accelerating research and drug development efforts for its clients [3] - Charles River's dedicated employees aim to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies [3]

Group 1 - Fortrea Holdings Inc. (NASDAQ:FTRE) is considered one of the best young stocks to buy and hold for three years, with recent price target adjustments from Mizuho and Truist indicating positive market sentiment [1][2][3] - Mizuho raised its price target on Fortrea to $15 from $13 while maintaining a Neutral rating, citing a sequential slowdown in healthcare utilization despite easier comparisons from the previous year [1] - Truist upgraded Fortrea from Hold to Buy, setting a new price target of $22, based on enhanced operational performance, emerging commercial strength, and improved profit margins under new leadership [2] - Evercore ISI upgraded Fortrea from In Line to Outperform, significantly raising its price target to $25 from $14, highlighting an accelerating biopharma cycle and improved execution as key drivers [3] Group 2 - Fortrea Holdings Inc. operates as a contract research organization, providing biopharmaceutical product and medical device development solutions to pharmaceutical, biotech, and medical device customers globally [4]

Company Overview - Fortrea Holdings is a leading global contract research organization focused on advancing clinical development and providing innovative solutions to accelerate the transition from molecule to medicine [1] - The company was established in 2023 after spinning out from Labcorp, with its roots tracing back to Covance, which was acquired by Labcorp in 2015 [2] Leadership Presentation - The presentation at the 44th JPMorgan Healthcare Conference was led by CEO Anshul Thakral, with CFO Jill McConnell assisting during the Q&A session [1] - The conference serves as a platform for the company to engage with stakeholders and kickstart the year positively [2]

Core Insights - Inotiv, Inc. announced a strategic initiative to integrate LifeNet Health's proprietary TruVivo system into its Discovery and Translational Sciences business, enhancing its drug development capabilities [1][3] Group 1: Company Overview - Inotiv, Inc. is a leading contract research organization focused on nonclinical and analytical drug discovery and development services, aiming to improve efficiency and reduce costs in bringing new drugs and medical devices to market [4] - The company is dedicated to supporting research and development objectives while promoting a healthier and safer world [4] Group 2: Technology and Collaboration - LifeNet Health has developed the TruVivo system, which utilizes primary human hepatocytes with human-derived feeder cells to create in vitro models that better predict human responses to therapies, addressing significant challenges in drug development [2] - The integration of the TruVivo platform into Inotiv's offerings will enhance the alignment of preclinical models with human biology and expand human-relevant tissue models beyond the liver, facilitating innovation across various human diseases [3] Group 3: Mission and Vision - Both Inotiv and LifeNet Health share a mission to accelerate scientific innovation that translates into meaningful human impact, emphasizing the importance of human-relevant technologies in preclinical research [3][5]

Core Viewpoint - Charles River Laboratories announced its acquisition of a major supplier of non-human primates for approximately $510 million, aiming to enhance control over procurement processes [1] Company Summary - The acquisition is part of Charles River Laboratories' strategy to strengthen its supply chain and ensure a steady supply of non-human primates, which are critical for its contract research services [1] - The deal reflects the company's commitment to vertical integration within the industry, allowing for better management of resources and potentially reducing costs in the long term [1] Industry Summary - The contract research organization (CRO) sector is increasingly focusing on securing reliable sources of biological materials, such as non-human primates, to meet the growing demand for preclinical research [1] - This acquisition may signal a trend among CROs to consolidate supply chains and enhance operational efficiencies in response to market pressures [1]